염증성 장질환에서 5-aminosalicylate에 의해 발생한 재발성 급성 심낭염 = CASE REPORT : Recurrent Acute Pericarditis Induced by 5-aminosalicylates in a Patient with Inflammatory Bowel Disease

다국어 초록 (Multilingual Abstract)

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammation of the intestines. IBD treatment may require anti-inflammatory agents such as sulfasalazine or 5-aminosalicylate (5-ASA) and immunomodulators to control the symptoms. However, these agents have a variety of common adverse effects such as nausea, vomiting, skin rash, leukopenia, thrombocytopenia, and infections. Moreover, rare side effects such as nephrotic syndrome, pneumonitis, and pericarditis can occur. A 21-year-old male was admitted to the hospital due to acute chest pain, fever, and sweating. The patient had a history of Crohn`s disease and had been taking mesalazine for 3 weeks. Chest x-ray, echocardiography, and clinical manifestations revealed that the patient had acute pericarditis. However, we did not recognize the relationship between these findings and 5-ASA at that time. Two years later, the patient took 5-ASA again, and similar symptoms occurred, which led us to confirm that he suffered from pericarditis induced by this drug. We report a case of acute recurrent pericarditis that developed after taking 5-ASA for IBD treatment with a review of the literature. (Intest Res 2012;10:289-294)

참고문헌 (Reference)

1 Faubion WA Jr, "The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study" 121 : 255-260, 2001

2 Leong RW, "The epidemiology and phenotype of Crohn's disease in the Chinese population" 10 : 646-651, 2004

3 Fraser AG, "The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review" 50 : 485-489, 2002

4 Loftus EV Jr, "Systematic review: short- term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis" 19 : 179-189, 2004

5 Woltsche M, "Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis" 6 : 495-497, 2001

6 Sentongo TA, "Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature" 27 : 344-347, 1998

7 Waite RA, "Possible mesalamine-induced pericarditis: case report and literature review" 22 : 391-394, 2002

8 Gujral N, "Pleuropericarditis related to the use of mesalamine" 41 : 624-626, 1996

9 Vayre F, "Pericarditis associated with longstanding mesalazine administration in a patient" 68 : 243-245, 1999

10 Geboes K, "Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept--what's in a name?" 14 : 850-857, 2008

11 Kaiser GC, "Massive pericardial effusion in a child following the administration of mesalamine" 25 : 435-438, 1997

12 김은수, "Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics" 거트앤리버 발행위원회 4 (4): 1-14, 2010

13 Aberer W, "European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations" 58 : 854-863, 2003

14 Agnholt J, "Cardiac hypersensitivity to 5-aminosalicylic acid" 1 : 1135-, 1989

15 Sturdevant RA, "Azathioprine-related pancreatitis in patients with Crohn's disease" 77 : 883-886, 1979

16 Ishikawa N, "Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis" 40 : 901-904, 2001

17 Candy S, "A controlled double blind study of azathioprine in the management of Crohn's disease" 37 : 674-678, 1995